John D Quisel sold $1.3M of IRON
Chief Executive Officer at Disc Medicine, Inc.. 19,820 shares at an average of $63.14, traded Dec 23, 2024, filed Dec 26, 2024.
Score components
- +25RoleCEO
- +25Trade size$1.3M at market
- +5Share of holdings soldSold 22% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-140502, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 23, 2024 | MOption exercise Common Stock10b5-1 | +19,820 | $2.65 | $53k | 91,885 | Dec 26, 2024 |
| Dec 23, 2024 | SOpen-market sale Common Stock10b5-1 | -3,414 | $62.38 | $213k | 88,471 | Dec 26, 2024 |
| Dec 23, 2024 | SOpen-market sale Common Stock10b5-1 | -12,194 | $63.12 | $770k | 76,277 | Dec 26, 2024 |
| Dec 23, 2024 | SOpen-market sale Common Stock10b5-1 | -4,212 | $63.80 | $269k | 72,065 | Dec 26, 2024 |
| Dec 23, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -19,820 | $0.00 | $0 | 41,830 | Dec 26, 2024 |
Related signals
Other insiders at Disc Medicine, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | IRONsell Disc Medicine, Inc. | Kevin Bitterman director | $1.9M 27,136 shares | -100% | |
| 6Weak | Disc Medicine, Inc. | Kevin Bitterman director | $135k 1,689 shares | -1% | |
| 25Weak | Disc Medicine, Inc. | Kevin Bitterman director | $4.4M 54,496 shares | -16% | |
| 6Weak | Disc Medicine, Inc. | Kevin Bitterman director | $140k 2,287 shares | -0% | |
| 20Weak | Disc Medicine, Inc. | Kevin Bitterman director | $2.0M 32,174 shares | -5% | |
| 0Weak | Disc Medicine, Inc. | Kevin Bitterman director | $24k 395 shares | -0% | |
| 21Weak | Disc Medicine, Inc. | Kevin Bitterman director | $518k 8,492 shares | -1% | |
| 55Moderate | Disc Medicine, Inc. | Kevin Bitterman director | $2.6M 42,870 shares | -6% | |
| 36Weak | Disc Medicine, Inc. | Kevin Bitterman director | $41k 664 shares | -0% | |
| 27Weak | Disc Medicine, Inc. | Jean M. Franchi Chief Financial Officer | $120k 2,031 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.